This week, the University of Zaragoza presented the “Nanomedicine Spain” awards for the best scientific papers published in 2025, at a ceremony held in Madrid which coincided with the official launch of the Spanish Society of Nanomedicine (SENM). The event brought together around a hundred researchers and experts from the biomedical and nanotechnology fields at the Institute of Materials Science in Madrid (ICMM-CSIC) and featured a notable presence from INMA (CSIC-UNIZAR).
These awards, promoted by the Cátedra Exobiopharma de Nanomedicina, led by our colleague Jesús Santamaría, a UNIZAR researcher at INMA (CSIC-UNIZAR), aim to recognise scientific excellence in nanomedicine developed in Spain and highlight its impact in areas such as diagnostics, advanced therapies and drug delivery systems.
In this first edition, 24 nominations were received from universities, healthcare institutes and leading research centres, including INMA itself and other CSIC centres.
The main prize was awarded to Álvaro Somoza (IMDEA Nanoscience) for a paper published in Nature Communications, whilst the runner-up prize went to María Concepción Serrano López-Terradas (Madrid Institute of Materials Science, CSIC), for her research published in Bioactive Materials. The prizes are worth €5,000 and €2,000 respectively.
The Spanish Society of Nanomedicine is launched
The awards ceremony took place as part of the inaugural event of the SENM, a new organisation established with the aim of bringing together the nanomedicine research community in Spain and enhancing the visibility and impact of this discipline. And INMA will play a key role in this new drive for nanomedicine in Spain, as our colleague Lucía Gutiérrez, a CSIC researcher at the institute, serves as secretary on the SENM’s board of directors.
A member of the Bionanosurf group, her research focuses on the use of magnetic nanoparticles for biomedical applications, such as cancer treatment. She is also co-coordinator of the CSIC’s Nanomedicine Connection.
INMA’s participation in this event reinforces our role as a leader in nanoscience and our contribution to the development of innovative solutions in the biomedical field, in line with the major challenges facing the medicine of the future.
